199 related articles for article (PubMed ID: 18219288)
1. A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Kang HJ; Chang HM; Kim TW; Ryu MH; Sohn HJ; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Br J Cancer; 2008 Jan; 98(2):316-22. PubMed ID: 18219288
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
Baize N; Abakar-Mahamat A; Mounier N; Berthier F; Caroli-Bosc FX
Cancer Chemother Pharmacol; 2009 Aug; 64(3):549-55. PubMed ID: 19123051
[TBL] [Abstract][Full Text] [Related]
3. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
[TBL] [Abstract][Full Text] [Related]
4. The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
Gong J; Hu B; Zhang X; Zhang F; Zhang J; Xu N; Fan Q; Bai Y; Jiao S; Wang J; Bai C; Zheng L; Shi Y; Liu Y; Liang J; Hu G; Cheng Y; Xu R; Bai Y; Shen L
Oncologist; 2014 Feb; 19(2):173-4. PubMed ID: 24457378
[TBL] [Abstract][Full Text] [Related]
5. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
Kim C; Lee JL; Ryu MH; Chang HM; Kim TW; Lim HY; Kang HJ; Park YS; Ryoo BY; Kang YK
Invest New Drugs; 2011 Apr; 29(2):366-73. PubMed ID: 19997960
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Yun T; Han JY; Lee JS; Choi HL; Kim HY; Nam BH; Kim HT
BMC Cancer; 2011 Sep; 11():385. PubMed ID: 21888637
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Oh SC; Sur HY; Sung HJ; Choi IK; Park SS; Seo JH; Jeen YT; Chun HJ; Shin SW; Mok YJ; Kim JS; Kim YH
Br J Cancer; 2007 May; 96(10):1514-9. PubMed ID: 17473829
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA;
Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer.
Park YH; Ryoo BY; Choi SJ; Kim HT
Br J Cancer; 2004 Apr; 90(7):1329-33. PubMed ID: 15054450
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Tonyali O; Benekli M; Berk V; Coskun U; Ozkan M; Yildiz R; Ucgul E; Sevinc A; Uncu D; Demirci U; Buyukberber S;
J Cancer Res Clin Oncol; 2013 Jun; 139(6):981-6. PubMed ID: 23463098
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
13. Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Gao J; Lu M; Yu JW; Li YY; Shen L
BMC Cancer; 2011 May; 11():177. PubMed ID: 21586171
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
Luo HY; Wang ZQ; Wang FH; Qiu MZ; Teng KY; Ruan DY; He YJ; Li YH; Xu RH
Am J Clin Oncol; 2011 Dec; 34(6):555-60. PubMed ID: 22101386
[TBL] [Abstract][Full Text] [Related]
16. A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
Chao Y; Hsieh JS; Yeh HT; Su YC; Wu CC; Chen JS; Tai CJ; Bai LY; Yeh KH; Su WC; Li CP
Cancer Chemother Pharmacol; 2014 Apr; 73(4):799-806. PubMed ID: 24531611
[TBL] [Abstract][Full Text] [Related]
17. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Xiang XJ; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
Chemotherapy; 2012; 58(1):1-7. PubMed ID: 22310723
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Kim TW; Kang YK; Ahn JH; Chang HM; Yook JH; Oh ST; Kim BS; Lee JS
Ann Oncol; 2002 Dec; 13(12):1893-8. PubMed ID: 12453857
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]